Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nidal Al-Huniti

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|October 17, 2022
Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancerJenny-Hoa Nguyen, Daniel Epling, Nancy Dolphin, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 3, 2019
Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling ApproachDiansong Zhou, Terry Podoll, Yan Xu, et al.
Clinical Pharmacokinetics|October 26, 2018
Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology PatientsDiansong Zhou, Jianguo Li, Khanh Bui, et al.
Clinical Pharmacology and Therapeutics|December 27, 2018
Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology PatientsDiansong Zhou, Jianguo Li, Maria Learoyd, et al.
Journal of Clinical Pharmacology|July 8, 2015
Reporting guidelines for population pharmacokinetic analysesKevin Dykstra, Nitin Mehrotra, Christoffer Wenzel Tornøe, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 30, 2021
A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumabMasood Khaksar Toroghi, Jim Bosley, Lyn M Powell, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 1, 2015
Reporting guidelines for population pharmacokinetic analysesKevin Dykstra, Nitin Mehrotra, Christoffer Wenzel Tornøe, et al.
Journal of Clinical Pharmacology|June 7, 2018
Population Pharmacokinetic Modeling With Enterohepatic Circulation for AZD3241 in Healthy Subjects and Patients With Multiple System AtrophyXiao Tong, Diansong Zhou, Alicia Savage, et al.
Journal for Immunotherapy of Cancer|March 1, 2018
Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems modelYuri Kosinsky, Simon J Dovedi, Kirill Peskov, et al.
Clinical Pharmacology and Therapeutics|February 26, 2019
Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development StrategiesLi Zhou, Mitsuo Higashimori, Kai Shen, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
CPT: Pharmacometrics & Systems Pharmacology|October 17, 2022
Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancerJenny-Hoa Nguyen, Daniel Epling, Nancy Dolphin, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 3, 2019
Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling ApproachDiansong Zhou, Terry Podoll, Yan Xu, et al.
Clinical Pharmacokinetics|October 26, 2018
Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology PatientsDiansong Zhou, Jianguo Li, Khanh Bui, et al.
Clinical Pharmacology and Therapeutics|December 27, 2018
Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology PatientsDiansong Zhou, Jianguo Li, Maria Learoyd, et al.
Journal of Clinical Pharmacology|July 8, 2015
Reporting guidelines for population pharmacokinetic analysesKevin Dykstra, Nitin Mehrotra, Christoffer Wenzel Tornøe, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 30, 2021
A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumabMasood Khaksar Toroghi, Jim Bosley, Lyn M Powell, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 1, 2015
Reporting guidelines for population pharmacokinetic analysesKevin Dykstra, Nitin Mehrotra, Christoffer Wenzel Tornøe, et al.
Journal of Clinical Pharmacology|June 7, 2018
Population Pharmacokinetic Modeling With Enterohepatic Circulation for AZD3241 in Healthy Subjects and Patients With Multiple System AtrophyXiao Tong, Diansong Zhou, Alicia Savage, et al.
Journal for Immunotherapy of Cancer|March 1, 2018
Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems modelYuri Kosinsky, Simon J Dovedi, Kirill Peskov, et al.
Clinical Pharmacology and Therapeutics|February 26, 2019
Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development StrategiesLi Zhou, Mitsuo Higashimori, Kai Shen, et al.
Pageof 6